
SaaS-based active-safety analytics and clinical agentic-AI layer for pharmacovigilance, epidemiology and medical-affairs teams at biopharma sponsors and CROs, differentiated by use of the FDA Sentinel Common Data Model and TreeScan signal-detection methodology on real-world data, and by a clinical-tuned LLM ("Clinical-LM") that powers modular AI agents.
Naming caveat: Saama's product catalogue includes no offering named "Saama Vigilance" or "Saama Genie" as of 2026-05-14. The closest match for the pharmacovigilance product is Active Safety Analytics for Pharma (ASAP), co-built with Gilead Sciences (launched 2020-10-26) with scientific advice from the Reagan-Udall Foundation for the FDA. The closest match for the "agentic AI layer" is Saama's Agentic AI Framework and its associated Clinical AI Agents, launched 2025-09-29. Saama's platform menu does not contain a "Vigilance" or "Genie" entry.
ASAP is an analytics engine — not a case-management or ICSR-processing system. It applies the FDA Sentinel Common Data Model and the TreeScan methodology over real-world data (insurance claims and EMR) to surface previously unknown drug–outcome associations, support competitor safety-profile comparison, and respond to regulator queries. Reported scale: "longitudinal data from 150 million patients over the past 15 years."
The Agentic AI Framework is a modular layer that hosts specialized Clinical AI Agents — for tasks such as patient narrative generation, inclusion/exclusion criteria drafting, data review, anomaly detection — designed to function under "partial autonomy" with human-in-the-loop oversight. Underlying foundation model is "Clinical-LM," a proprietary clinical LLM. Saama states it is the first vendor to commercialise the FDA Sentinel Common Data Model and TreeScan methodology in a pharma-facing product.
Target buyer for ASAP: PV, epidemiology and medical-affairs leaders at sponsors that already run a primary safety case-processing system and want to overlay active surveillance on RWD. Target buyer for the Agentic AI Framework: heads of clinical data management, biometrics and study operations seeking to attach AI agents to existing systems.
Saama is wholly focused on life sciences. ASAP is the PV-specific analytics product (Sentinel CDM + TreeScan). Cross-vertical analytics work is spun out as Astraa, narrowing Saama's strategy to life sciences.
Deployment: SaaS, hosted on AWS infrastructure. "Saama's SaaS Platform and Clinical AI and Analytics Solutions and Services (CaaS) leverages AWS infrastructure and platform services." Saama Platform Enterprise listed on AWS Marketplace. Multi-tenant vs single-tenant mapping not publicly specified. Cloud regions / data residency (EU, China, India, GovCloud) not enumerated.
Access: browser-based; SSO via SAML, OAuth, and LDAP; MFA required for "critical systems"; supports Federated Identity Management for customer-managed identities. Native mobile apps not documented. Named connectors (Azure AD, Okta) not enumerated; SAML alignment generally enables these.
API maturity: Agentic AI Framework explicitly describes agents "connected via APIs." REST vs GraphQL specifics, webhook catalog, rate limits, SDKs not published.
Encryption: AES-256 at rest, TLS 1.2/1.3 in transit, FIPS 140-2 algorithms.
Data standards supported: CDISC SDTM (BRAIN SDTM product); SAS workflows (BRAIN SCE); FDA Sentinel Common Data Model (ASAP). E2B (R2/R3), MedDRA, WHODrug, HL7, FHIR — not documented as native standards on product pages.
Scale: Pfizer COVID-19 vaccine trial — SDQ processed tens of millions of data points for a 44,000-person trial and enabled 22-hour post-trial data review. LSAC used on "more than 1,500 studies" by "more than 50 biopharmaceutical companies" (vendor reports, dating to 2020).
Pricing model not published. Saama listed in AWS Marketplace as "Private Offers Only," indicating enterprise-only quoting. Per-user vs per-tenant vs per-case vs consumption breakdown not enough information.
No starting price is published. Demo is the standard inbound CTA; no self-serve free trial offered.
Reported deal sizes by customer segment: not enough information. Multi-year enterprise agreements with Pfizer (initial 2020, expanded 2024) and AstraZeneca (2023) imply $1M+ enterprise deal sizes for top-20 pharma, but dollar values not disclosed. Minimum commitments, setup fees, and validation-support fees not enough information.
Typical timeline by org size: vendor reports configuration "in a few days to weeks." Independent timeline-by-tier benchmarks not enough information.
Services included with license vs priced separately: not enumerated publicly. Saama markets discrete service lines — Bespoke LLM Tuning, LLM Operations, Prompt Engineering, Platform Architecture & Strategy, Use Case Identification, RAG accelerator, PII Scrubber, Generative Reporting — which signals substantial professional-services attach.
Migration capabilities: Saama references compatibility "with all IT and data infrastructure" and journeys from traditional relational databases to Snowflake. No named legacy-system migrator is documented; ASAP is not marketed as a case-processing replacement.
Common implementation pitfalls: AWS Marketplace G2-sourced commentary surfaces a user-reported concern about resource availability ("often takes time to get hold of enough resources from them to expedite your progress"). Indeed employee-review commentary alleges sales sometimes "sell the idea of the product… and then scramble around to build it when the client agrees."
Anonymous feedback from pharmaceutical professionals using this solution
4.0 out of 5
Based on 2 verified reviews
One G2 reviewer wrote, "Saama got really good talent to take care of your data needs… they will be partner when designing your specific solution. Their cooperation and expertise is what we liked the most." A second G2 reviewer cited that Saama "provide all the details for implementation. Their customer support is really good." Everest Group highlights Saama's "continuously being at the forefront of AI and GenAI application in the clinical D&A value chain" and "responsiveness of support services, as well as proactiveness."
Users report resource-availability constraints. One G2 reviewer wrote, "though Saama has one for he what talent, it often takes time to get hold of enough resources from them to expedite your progress." Indeed employee-review commentary alleges that "sales exaggerates our capabilities" and that the company at times sells the product concept and builds during implementation. Public review coverage is limited to two G2 reviews. ASAP is not a 21 CFR Part 11 system of record. It does not publicly document e-signature workflows, GAMP 5 self-classification, IQ/OQ/PQ packages, SOC 2 Type II availability, E2B(R3) handling, MedDRA-coded ICSR workflows, or formal data-portability commitments.
Share your experience with Saama Active Safety Analytics for Pharma (ASAP) + Agentic AI Framework anonymously. Your insights help pharmaceutical professionals make better software decisions.
Contribute Anonymous FeedbackPublicly disclosed pharmaceutical and biotech organizations
Jump to section